Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-21

Clinical Trial Update: A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of afatinib (BIBW 2992) in metastatic colorectal cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-21